33,919 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Purchased by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the 3rd quarter, Holdings Channel reports. The firm bought 33,919 shares of the medical technology company’s stock, valued at approximately $189,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Comerica Bank grew its holdings in shares of Alphatec by 64.8% in the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after acquiring an additional 2,534 shares during the period. Van ECK Associates Corp grew its holdings in Alphatec by 11.8% in the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 1,300 shares during the last quarter. Cetera Advisors LLC increased its position in shares of Alphatec by 15.6% in the first quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after buying an additional 1,720 shares in the last quarter. Net Worth Advisory Group acquired a new position in shares of Alphatec during the 3rd quarter worth $76,000. Finally, SG Americas Securities LLC boosted its position in shares of Alphatec by 44.6% in the 2nd quarter. SG Americas Securities LLC now owns 14,495 shares of the medical technology company’s stock worth $151,000 after buying an additional 4,472 shares in the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on ATEC. Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Friday, August 30th. Lake Street Capital cut their price objective on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Thursday, October 31st. Needham & Company LLC reissued a “buy” rating and set a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Finally, Barclays upped their price objective on Alphatec from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.11.

Alphatec Trading Up 0.4 %

Shares of Alphatec stock opened at $9.63 on Friday. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $17.34. The business’s fifty day moving average is $7.55 and its two-hundred day moving average is $8.18. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm has a market cap of $1.36 billion, a PE ratio of -7.52 and a beta of 1.38.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.